Advanced in Prostate Cancer

Siobhan S. Ng

Perth, WA, AU 
Advanced in Prostate Cancer
Perth, WA, AU 
OverviewLocationsClinical Research

Overview

Siobhan Ng practices in Perth, Australia. Ms. Ng is rated as an Advanced expert by MediFind in the treatment of Prostate Cancer. Her top areas of expertise are Prostate Cancer, Muscle Invasive Bladder Cancer, Bone Tumor, and Pericarditis.

Her clinical research consists of co-authoring 20 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 16 articles in the study of Prostate Cancer.

Gender
Female

Locations

Perth, WA, Australia
Other Locations
Nedlands, WA, Australia
St John Of God Private Hospital, Subiaco, WA, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
View 1 Less Clinical Trial

20 Total Publications

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: April 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Ng's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile